SAN FRANCISCO – "Platforms are 'in' again," said Arthur Sands, CEO of Nurix Inc., which last September bagged an agreement with Celgene Corp. that brought $150 million up front plus an undisclosed equity investment to discover and develop drugs that target the ubiquitin proteasome system (UPS).